Indication

For the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.

Medicine details

Medicine name:
cerliponase alfa (Brineura)
SMC ID:
SMC2286
Pharmaceutical company
BioMarin
BNF chapter
Central nervous system
Submission type
Ultra-orphan initial assessment
Publication due date:
12 October 2020
SMC meeting date:
01 September 2020
Patient group submission deadline:
03 August 2020